Synbio International Inc. (OTC: SYIN) announced execution of a Master Services Agreement with CRO Services Pty Ltd, an Australian clinical research organization and subsidiary of ASX-listed Resonance Health Ltd.
Trial Overview
CRO Services will conduct a proof-of-concept clinical trial in Australia to evaluate FacialDx’s NIMS™ (Non-invasive Medical Screening) technology. The AI-powered facial analysis tool is designed to identify early-stage indicators of Post-Traumatic Stress Disorder and Major Depressive Disorder.
Clinical Validation
The trial will assess the technology’s accuracy, reliability, and clinical utility under real-world conditions.
“Clinical validation is the foundation for regulatory engagement and commercial deployment,” Synbio’s CEO said. The study represents a critical step toward potential FDA engagement and commercial adoption.
Market Opportunity
Mental health is discussed in approximately 150 million U.S. primary care visits annually. Current screening relies heavily on subjective questionnaires and self-reporting; the technology aims to provide objective biological data, potentially offering what the company describes as “the world’s first objective screening test for a mental health condition.”
Timeline and Next Steps
The trial is expected to commence in early 2026 and conclude later that year. Final execution remains subject to completion of supporting agreements and cost schedules.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.